Background: China's Expanded Program on Immunization (EPI) provides vaccinations against 12 vaccine preventable diseases (VPDs) at no cost to families. For some VPDs, parents may opt to substitute equivalent non-program vaccines, including combination vaccines, for EPI vaccines; substitute vaccines must be paid for by the family. Although parents have several choices for vaccinating their children, their preferences for vaccines and immunization schedules have not been systematically evaluated. We used a discrete choice experiment to evaluate four attributes of vaccines for routine immunization: number of injections, risk of mild side-effects, out-of-pocket cost, and location of manufacturer (domestic or imported).
Methods: In a questionnaire-based survey conducted in vaccination clinics, guardians were asked to select their preferred vaccination schedule from five options in ten choice sets with the four attributes. We used a mixed logit model to determine parental preferences for vaccination schedules, relative importance of attributes, and predict the likelihood of successful vaccination under different scenarios.
Results: A total of 581 parents from seven provinces and cities in China participated in the survey, and 488 respondents had internally consistent responses and were included in the analysis. The number of injections in the schedule was the most important attribute for predicting uptake, followed by risk of mild side-effects. Preferences varied by region and parental role. Predicted uptake in the preferred vaccination scenario relative to base-case schedule uptake was a 99.55 % increase.
Conclusions: Number of injections and risk of mild side-effects were the two most important attributes of the routine immunization schedule. Results from this study can help optimize the immunization schedule in China to improve coverage of childhood vaccines.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728966 | PMC |
http://dx.doi.org/10.1016/j.jvacx.2024.100602 | DOI Listing |
Graefes Arch Clin Exp Ophthalmol
January 2025
15-20 National Ophthalmologic Center, Paris, France.
Purpose: Intravitreal injections of anti-VEGF agents are considered as safe, with a very low rate of intraocular inflammations (IOI). Faricimab is a novel intravitreal bispecific antibody targeting both VEGF-A and angiopoietin-Tie2 independently. Despite a safe profile in randomized clinical trials, several real-life studies have reported cases of IOI.
View Article and Find Full Text PDFVaccine X
January 2025
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Background: China's Expanded Program on Immunization (EPI) provides vaccinations against 12 vaccine preventable diseases (VPDs) at no cost to families. For some VPDs, parents may opt to substitute equivalent non-program vaccines, including combination vaccines, for EPI vaccines; substitute vaccines must be paid for by the family. Although parents have several choices for vaccinating their children, their preferences for vaccines and immunization schedules have not been systematically evaluated.
View Article and Find Full Text PDFBMJ Open
December 2024
Disease Elimination, Burnet Institute, Melbourne, Victoria, Australia
Introduction: Opioid overdose and blood-borne virus transmission are key health risks for people who inject drugs. Existing study methods that record data on injecting drug risks mostly rely on retrospective self-reporting that, while valid, are limited to being broad and subject to recall bias. The In-The-Moment-Expanded (ITM-Ex) study will evaluate the feasibility and acceptability of multiple novel data collection methods to capture in situ drug injecting data.
View Article and Find Full Text PDFBMJ Open
December 2024
Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetric & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China
Introduction: Compared with the guideline-recommended use of low-molecular weight heparin (LMWH) for 28 days to prevent venous thromboembolism (VTE) after cytoreductive surgery, oral rivaroxaban avoids the pain and inconvenience of daily injections and reduces medical expenses. The proposed randomised controlled trial (RCT) aims to compare the efficacy and safety of rivaroxaban and enoxaparin in preventing VTE in patients after surgery for gynaecological malignancies and to provide a reference for clinical medication prevention.
Methods And Analysis: This is a single-centre, randomised, controlled, open-label and assessor-blind clinical trial.
BMJ Open
December 2024
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Introduction: Young women are disproportionately affected by HIV in South Africa and have a high incidence of unintended pregnancies. Access to sexual and reproductive health (SRH) services, including HIV pre-exposure prophylaxis (PrEP), contraception and screening for seally transmitted infections (STIs), remains limited in South Africa, in part due to inadequate infrastructure and individual barriers to care. Integrated, community-based SRH services have the potential to overcome barriers to clinic-based care for women at risk of HIV, unintended pregnancy and STIs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!